1
|
Pang Y, Sun Y, Wu Y, Li J, Qin P, Guo S, Zhou W, Chen J, Wang J. Targeting the ZMIZ1-Notch1 signaling axis for the treatment of tongue squamous cell carcinoma. Sci Rep 2024; 14:13577. [PMID: 38866828 PMCID: PMC11169241 DOI: 10.1038/s41598-024-59882-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2024] [Accepted: 04/16/2024] [Indexed: 06/14/2024] Open
Abstract
Zinc finger MIZ-type containing 1 (ZMIZ1) is a transcriptional coactivator related to the protein inhibitors of activated STATs (PIAS) family. Mounting evidence suggests that ZMIZ1 plays a crucial role in the occurrence and development of cancers. The function of ZMIZ1 in tongue squamous cell carcinoma (TSCC) and the mechanisms underpinning its role in this disease have not been fully clarified. We performed qualitative ZMIZ1 protein expression analyses using immunohistochemistry in 20 patient-derived, paraffin-embedded TSCC tissue sections. We used RNAi to knock down ZMIZ1 expression in the CAL-27 TSCC cell line and quantified the impact of ZMIZ1 knock down on proliferation, migration and apoptosis via CCK-8, scratch assay and flow cytometry, respectively. We used qRT-PCR and western blotting to investigate the role of ZMIZ1 in this cell line. Finally, we established a model of lung metastasis in nude mice to replicate the in vitro results. ZMIZ1 protein was significantly more abundant in TSCC case tissue samples. ZMIZ1 knockdown reduced the invasion and metastases of TSCC tumor cells and promoted apoptosis. ZMIZ1 knockdown was associated with the down-regulation of Notch signaling pathway related factors Jagged1 and Notch1, and invasion and metastasis related factors MKP-1, SSBP2 and MMP7 in vitro and in vivo, at the mRNA level. In vitro and in vivo data suggest that knock down of ZMIZ1 may inhibit TSCC invasion and metastasis by modulating Notch signaling. ZMIZ1 inhibition may therefore represent a new therapeutic target for TSCC.
Collapse
Affiliation(s)
- Yunqing Pang
- Lanzhou University, Lanzhou, 730000, Gansu, China
- Clinical Research Center for Oral Diseases, Lanzhou, 730000, Gansu, China
| | - Yunjie Sun
- Lanzhou University, Lanzhou, 730000, Gansu, China
- Clinical Research Center for Oral Diseases, Lanzhou, 730000, Gansu, China
| | - Yuyan Wu
- Lanzhou University, Lanzhou, 730000, Gansu, China
- Clinical Research Center for Oral Diseases, Lanzhou, 730000, Gansu, China
| | - Jiamin Li
- Lanzhou University, Lanzhou, 730000, Gansu, China
- Clinical Research Center for Oral Diseases, Lanzhou, 730000, Gansu, China
| | - Pingchuan Qin
- Lanzhou University, Lanzhou, 730000, Gansu, China
- Clinical Research Center for Oral Diseases, Lanzhou, 730000, Gansu, China
| | - Shanchuan Guo
- Lanzhou University, Lanzhou, 730000, Gansu, China
- Clinical Research Center for Oral Diseases, Lanzhou, 730000, Gansu, China
| | - Wenlian Zhou
- Clinical Education Woody L. Hunt School of Dental Medicine, Dental Medicine Texas Tech University Health Sciences Center El Paso, El Paso, Texas, 79905, USA
| | - Jian Chen
- The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
| | - Jing Wang
- Lanzhou University, Lanzhou, 730000, Gansu, China.
- Clinical Research Center for Oral Diseases, Lanzhou, 730000, Gansu, China.
| |
Collapse
|
2
|
Nopora A, Weidle UH. CircRNAs as New Therapeutic Entities and Tools for Target Identification in Acute Myeloid Leukemia. Cancer Genomics Proteomics 2024; 21:118-136. [PMID: 38423599 PMCID: PMC10905271 DOI: 10.21873/cgp.20434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 01/08/2024] [Accepted: 01/09/2024] [Indexed: 03/02/2024] Open
Abstract
Acute myeloid leukemia (AML) is a genetically extremely heterogeneous disease. Drug resistance after induction therapy is a very frequent event resulting in poor medium survival times. Therefore, the identification of new targets and treatment modalities is a medical high priority issue. We addressed our attention to circular RNAs (circRNAs), which can act as oncogenes or tumor suppressors in AML. We searched the literature (PubMed) and identified eight up-regulated and two down-regulated circ-RNAs with activity in preclinical in vivo models. In addition, we identified twenty-two up-regulated and four down-regulated circRNAs with activity in preclinical in vitro systems, but pending in vivo activity. Up-regulated RNAs are potential targets for si- or shRNA-based approaches, and down-regulated circRNAs can be reconstituted by replacement therapy to achieve a therapeutic benefit in preclinical systems. The up-regulated targets can be tackled with small molecules, antibody-based entities, or other modes of intervention. For down-regulated targets, up-regulators must be identified. The ranking of the identified circRNAs with respect to therapy of AML will depend on further target validation experiments.
Collapse
Affiliation(s)
- Adam Nopora
- Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Ulrich H Weidle
- Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| |
Collapse
|
3
|
Dong W, Zhang H, Li Q, Guan N, Yun C, Zhao H, Zhang F, Zeng Z, Hu Y, Li Q, Yang J, Ma Z, Chen M, Xiao W. A novel prognostic signature contributes to precision treatment in colon adenocarcinoma with KRAS mutation. Eur J Cancer Prev 2023; 32:557-565. [PMID: 37310401 DOI: 10.1097/cej.0000000000000819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
BACKGROUND Approximately 40% of colon cancer harbor Kirsten rat sarcoma viral oncogene ( KRAS ) mutations, but the prognostic value of KRAS mutations in colon cancer is still controversial. METHODS We enrolled 412 colon adenocarcinoma (COAD) patients with KRAS mutations, 644 COAD patients with KRAS wild-type and 357 COAD patients lacking information on KRAS status from five independent cohorts. A random forest model was developed to estimate the KRAS status. The prognostic signature was established using least absolute shrinkage and selection operator-Cox regression and evaluated by Kaplan-Meier survival analysis, multivariate-Cox analysis, receiver operating characteristic curve and nomogram. The expression data of KRAS -mutant COAD cell lines from the Cancer Cell Line Encyclopedia database and the corresponding drug sensitivity data from the Genomics of Drug Sensitivity in Cancer database were used for potential target and agent exploration. RESULTS We established a 36-gene prognostic signature classifying the KRAS -mutant COAD as high and low risk. High risk patients had inferior prognoses compared to those with low risk, while the signature failed to distinguish the prognosis of COAD with KRAS wild-type. The risk score was the independent prognostic factor for KRAS -mutant COAD and we further fabricated the nomograms with good predictive efficiency. Moreover, we suggested FMNL1 as a potential drug target and three drugs as potential therapeutic agents for KRAS -mutant COAD with high risk. CONCLUSION We established a precise 36-gene prognostic signature with great performance in prognosis prediction of KRAS -mutant COAD providing a new strategy for personalized prognosis management and precision treatment for KRAS -mutant COAD.
Collapse
Affiliation(s)
- Weiwei Dong
- Senior Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing
| | - He Zhang
- Jinzhou Medical University, Liaoning
- Department of Oncology, The Fourth Medical Center of Chinese PLA General Hospital
| | - Qingyan Li
- Jinzhou Medical University, Liaoning
- Department of Oncology, The Fourth Medical Center of Chinese PLA General Hospital
| | - Na Guan
- Jinzhou Medical University, Liaoning
- Department of Oncology, The Fourth Medical Center of Chinese PLA General Hospital
| | - Chao Yun
- Jinzhou Medical University, Liaoning
- Department of Oncology, The Fourth Medical Center of Chinese PLA General Hospital
| | - Huixia Zhao
- Department of Oncology, The Fourth Medical Center of Chinese PLA General Hospital
| | - Fengyun Zhang
- Department of Oncology, The Fourth Medical Center of Chinese PLA General Hospital
| | - Zhiyan Zeng
- Department of Oncology, The Fourth Medical Center of Chinese PLA General Hospital
| | - Yanyan Hu
- Senior Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing
| | - Qiuwen Li
- Senior Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing
| | - Jingwen Yang
- Senior Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing
| | - Zihuan Ma
- Department of Scientific Research Projects and
| | - Meiling Chen
- Department of Medical Products, ChosenMed, Beijing Economic-Technological Development Area, Beijing, China
| | - Wenhua Xiao
- Senior Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing
| |
Collapse
|
4
|
Minutentag IW, Seneda AL, Barros-Filhos MC, de Carvalho M, Souza VGP, Hasimoto CN, Moraes MPT, Marchi FA, Lam WL, Reis PP, Drigo SA. Discovery of Novel miRNAs in Colorectal Cancer: Potential Biological Roles and Clinical Utility. Noncoding RNA 2023; 9:65. [PMID: 37987361 PMCID: PMC10660700 DOI: 10.3390/ncrna9060065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 09/27/2023] [Accepted: 10/11/2023] [Indexed: 11/22/2023] Open
Abstract
Deregulated miRNAs are associated with colorectal cancer (CRC), with alterations depending on the tumor location. Novel tissue-specific miRNAs have been identified in different tumors and are associated with cancer. We used miRMaster to identify novel miRNAs in CRC from the TCGA and GEO data (discovery and validation groups). We used TCGA data from five tissues to analyze miRNA tissue specificity. miRDB was used to predict miRNA targets, and the UCSC Xena Browser was used to evaluate target expression. After successive analyses, we identified 15 novel miRNAs with the same expression patterns in CRC in both the discovery and validation groups. Four molecules (nov-miR-13844-5p, nov-miR-7154-5p, nov-miR-5035-3p, and nov-miR-590-5p) were differentially expressed in proximal and distal CRC. The nov-miR-3345-5p and nov-miR-13172-3p, which are upregulated in tumors, are only expressed in colorectal tissues. These molecules have been linked to a worse prognosis in right-sided colon and rectal carcinomas. An analysis revealed an association between eight novel miRNAs and 81 targets, mostly cancer-related genes, with varying expression based on tumor location. These findings provide new miRNAs with potential biological relevance, molecular biomarkers, and therapeutic targets for CRC treatment.
Collapse
Affiliation(s)
- Iael Weissberg Minutentag
- Department of Surgery and Orthopedics, Medical School, São Paulo State University (UNESP), Botucatu 18618-687, Brazil; (A.L.S.); (C.N.H.)
- Experimental Research Unity (UNIPEX), São Paulo State University (UNESP), Botucatu 18618-687, Brazil;
| | - Ana Laura Seneda
- Department of Surgery and Orthopedics, Medical School, São Paulo State University (UNESP), Botucatu 18618-687, Brazil; (A.L.S.); (C.N.H.)
- Experimental Research Unity (UNIPEX), São Paulo State University (UNESP), Botucatu 18618-687, Brazil;
| | - Mateus C. Barros-Filhos
- Centro Internacional de Pesquisa (CIPE)—A. C. Camargo Cancer Center, São Paulo 01508-010, Brazil
| | - Márcio de Carvalho
- School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu 18618-687, Brazil
| | - Vanessa G. P. Souza
- Experimental Research Unity (UNIPEX), São Paulo State University (UNESP), Botucatu 18618-687, Brazil;
- Department of Genetics, Institute of Biosciences, São Paulo State University (UNESP), Botucatu 18618-687, Brazil
| | - Claudia N. Hasimoto
- Department of Surgery and Orthopedics, Medical School, São Paulo State University (UNESP), Botucatu 18618-687, Brazil; (A.L.S.); (C.N.H.)
| | - Marcelo P. T. Moraes
- Department of Surgery and Orthopedics, Medical School, São Paulo State University (UNESP), Botucatu 18618-687, Brazil; (A.L.S.); (C.N.H.)
- Department of Pathology, Medical School, São Paulo State University (UNESP), Botucatu 18618-687, Brazil
| | - Fabio A. Marchi
- Department of Head and Neck Surgery, Medical School and São Paulo State Cancer Institute (ICESP), University of São Paulo (USP), São Paulo 01246-903, Brazil
| | - Wan L. Lam
- British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada
| | - Patricia P. Reis
- Department of Surgery and Orthopedics, Medical School, São Paulo State University (UNESP), Botucatu 18618-687, Brazil; (A.L.S.); (C.N.H.)
- Experimental Research Unity (UNIPEX), São Paulo State University (UNESP), Botucatu 18618-687, Brazil;
| | - Sandra A. Drigo
- Department of Surgery and Orthopedics, Medical School, São Paulo State University (UNESP), Botucatu 18618-687, Brazil; (A.L.S.); (C.N.H.)
- Experimental Research Unity (UNIPEX), São Paulo State University (UNESP), Botucatu 18618-687, Brazil;
| |
Collapse
|
5
|
Bang S, Son H, Cha H, Song K, Park H, Kim H, Ko JY, Myung J, Paik S. Immunohistochemical Analysis of Single-Stranded DNA Binding Protein 2 in Non-Melanoma Skin Cancers. Biomedicines 2023; 11:1818. [PMID: 37509458 PMCID: PMC10376428 DOI: 10.3390/biomedicines11071818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 06/13/2023] [Accepted: 06/23/2023] [Indexed: 07/30/2023] Open
Abstract
Single-stranded DNA binding protein 2 (SSBP2) is a tumor suppressor candidate. In this study, the expression level and clinicopathological significance of SSBP2 in squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) were evaluated. We also identified biological pathways associated with a set of genes potentially related to SSBP2. Immunohistochemistry (IHC) was performed on 70 SCC and 146 BCC cases to assess SSBP2 expression semi-quantitatively. In addition, the associations between SSBP2 expression and clinicopathological characteristics were analyzed. Gene ontology (GO) enrichment analysis was performed using publicly available data and web-based bioinformatics tools. Compared with BCC, SCC had a significantly low SSBP2 expression (p < 0.001). In total, 12 (17.1%) of the 70 SCC cases and 30 (20.5%) of the 146 BCC cases showed low SSBP2 expression. Among SCC cases, ulceration (p = 0.005) and a deep level of invasion (p = 0.012) showed an association with low SSBP2 expression. Local recurrence was slightly more common in the SCC subgroup with low SSBP2 expression, although the difference was not significant (p = 0.058). Using GO enrichment analysis, we identified several biological functions performed by a set of 36 genes in SCC. SSBP2 evaluation using IHC can be helpful in the differential diagnosis of SCC and BCC. SSBP2 expression was associated with tumor invasiveness in SCC.
Collapse
Affiliation(s)
- Seongsik Bang
- Department of Pathology, Seoul Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
| | - Hwangkyu Son
- Department of Pathology, Seoul Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
| | - Hyebin Cha
- Department of Pathology, Seoul Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
| | - Kihyuk Song
- Department of Pathology, Seoul Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
| | - Hosub Park
- Department of Pathology, Seoul Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
| | - Hyunsung Kim
- Department of Pathology, Seoul Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
| | - Joo Yeon Ko
- Department of Dermatology, Seoul Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
| | - Jaekyung Myung
- Department of Pathology, Seoul Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
| | - Seungsam Paik
- Department of Pathology, Seoul Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
| |
Collapse
|
6
|
Gill PS, Dweep H, Rose S, Wickramasinghe PJ, Vyas KK, McCullough S, Porter-Gill PA, Frye RE. Integrated microRNA–mRNA Expression Profiling Identifies Novel Targets and Networks Associated with Autism. J Pers Med 2022; 12:jpm12060920. [PMID: 35743705 PMCID: PMC9225282 DOI: 10.3390/jpm12060920] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Revised: 05/23/2022] [Accepted: 05/27/2022] [Indexed: 01/27/2023] Open
Abstract
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder, with mutations in hundreds of genes contributing to its risk. Herein, we studied lymphoblastoid cell lines (LCLs) from children diagnosed with autistic disorder (n = 10) and controls (n = 7) using RNA and miRNA sequencing profiles. The sequencing analysis identified 1700 genes and 102 miRNAs differentially expressed between the ASD and control LCLs (p ≤ 0.05). The top upregulated genes were GABRA4, AUTS2, and IL27, and the top upregulated miRNAs were hsa-miR-6813-3p, hsa-miR-221-5p, and hsa-miR-21-5p. The RT-qPCR analysis confirmed the sequencing results for randomly selected candidates: AUTS2, FMR1, PTEN, hsa-miR-15a-5p, hsa-miR-92a-3p, and hsa-miR-125b-5p. The functional enrichment analysis showed pathways involved in ASD control proliferation of neuronal cells, cell death of immune cells, epilepsy or neurodevelopmental disorders, WNT and PTEN signaling, apoptosis, and cancer. The integration of mRNA and miRNA sequencing profiles by miRWalk2.0 identified correlated changes in miRNAs and their targets’ expression. The integration analysis found significantly dysregulated miRNA–gene pairs in ASD. Overall, these findings suggest that mRNA and miRNA expression profiles in ASD are greatly altered in LCLs and reveal numerous miRNA–gene interactions that regulate critical pathways involved in the proliferation of neuronal cells, cell death of immune cells, and neuronal development.
Collapse
Affiliation(s)
- Pritmohinder S. Gill
- Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA;
- Arkansas Children′s Research Institute, Little Rock, AR 72202, USA; (K.K.V.); (S.M.); (P.A.P.-G.)
- Correspondence: ; Tel.: +1-501-364-2743
| | - Harsh Dweep
- The Wistar Institute, 3601 Spruce St., Philadelphia, PA 19104, USA; (H.D.); (P.J.W.)
| | - Shannon Rose
- Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA;
- Arkansas Children′s Research Institute, Little Rock, AR 72202, USA; (K.K.V.); (S.M.); (P.A.P.-G.)
| | | | - Kanan K. Vyas
- Arkansas Children′s Research Institute, Little Rock, AR 72202, USA; (K.K.V.); (S.M.); (P.A.P.-G.)
| | - Sandra McCullough
- Arkansas Children′s Research Institute, Little Rock, AR 72202, USA; (K.K.V.); (S.M.); (P.A.P.-G.)
| | - Patricia A. Porter-Gill
- Arkansas Children′s Research Institute, Little Rock, AR 72202, USA; (K.K.V.); (S.M.); (P.A.P.-G.)
| | - Richard E. Frye
- Barrow Neurological Institute at Phoenix Children′s Hospital, Phoenix, AZ 85016, USA;
- Department of Child Health, University of Arizona College of Medicine, Phoenix, AZ 85004, USA
| |
Collapse
|
7
|
Loss of Single-Stranded DNA Binding Protein 2 Expression Is Associated with Aggressiveness and Poor Overall Survival in Patients with Invasive Breast Carcinoma. Diagnostics (Basel) 2022; 12:diagnostics12020487. [PMID: 35204577 PMCID: PMC8871390 DOI: 10.3390/diagnostics12020487] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 01/28/2022] [Accepted: 02/12/2022] [Indexed: 02/01/2023] Open
Abstract
Background: Single-stranded DNA binding protein 2 (SSBP2) is involved in the DNA damage response and the maintenance of genome stability. Previous studies have suggested that SSBP2 has a tumor suppressor function or oncogenic function. Loss of SSBP2 expression has been reported in various tumors. However, the role of SSBP2 expression in invasive breast carcinoma has not been reported. Methods: Immunohistochemical staining for SSBP2 was performed on tissue microarrays consisting of 491 invasive breast carcinoma cases. The result of nuclear SSBP2 staining was stratified as either negative or positive. Then, we investigated the correlations between SSBP2 expression and various clinicopathological parameters and patient outcomes. Results: Loss of nuclear SSBP2 expression was observed in 61 cases (12.4%) of 491 invasive breast carcinomas. Loss of nuclear SSBP2 expression was significantly correlated with larger tumor size (p < 0.001, chi-squared test), higher histological grade (p = 0.016, Cochran–Armitage trend test), higher pathological T stage (p < 0.001, Cochran–Armitage trend test), estrogen receptor status (p < 0.001, chi-squared test), and molecular subtype (p < 0.001, chi-squared test). Kaplan–Meier survival analysis revealed that patients with loss of nuclear SSBP2 expression had worse overall survival (p = 0.013, log-rank test). However, loss of nuclear SSBP2 expression was not correlated with recurrence-free survival (p = 0.175, log-rank test). Conclusions: Loss of nuclear SSBP2 expression was associated with adverse clinicopathological characteristics and poor patient outcomes. SSBP2 acts as a tumor suppressor in invasive breast carcinoma and may be used as a prognostic biomarker.
Collapse
|